07:00 , Jun 30, 2008 |  BC Week In Review  |  Company News

Axentis, BioDevelops deal

Axentis acquired BioDevelops Pharma for an undisclosed amount. The acquisition gave Axentis exclusive rights to IP covering the use of molecules for the enzymatic removal of ubiquitin markers from incorrectly folded proteins. The company plans...